Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia

References

• Bei Hu, Ross L, Neuhaus J et al. Off-label medication use in frontotemporal dementia. Am. J. Alzheimers Dis. Other Demen.25(2), 128–133 (2010).
   PubMed Web of Science ®Google Scholar
• Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs24(5), 375–398 (2010).
   PubMed Web of Science ®Google Scholar
• Rascovsky KP, Hodges JR, Kipps CM et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis. Assoc. Disorders21(4), S14–S18 (2007).
   PubMed Web of Science ®Google Scholar
• Neary D, Snowden JS, Gustafson L et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology51(6), 1546–1554 (1998).
   PubMed Web of Science ®Google Scholar
• Mackenzie I, Neumann M, Bigio E et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol.119(1), 1–4 (2010).
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science314(5796), 130–133 (2006).
   PubMed Web of Science ®Google Scholar
• Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain132(Pt 11), 2922–2931 (2009).
   PubMed Web of Science ®Google Scholar
• Merrilees J. A model for management of behavioral symptoms in frontotemporal lobar degeneration. Alzheimer Dis. Assoc. Disord.21(4), S64–S69 (2007).
   PubMed Web of Science ®Google Scholar
• Talerico KA, Evans LK. Responding to safety issues in frontotemporal dementias. Neurology56(11 Suppl. 4), S52–S55 (2001).
   PubMed Web of Science ®Google Scholar
• Perry RJ, Miller BL. Behavior and treatment in frontotemporal dementia. Neurology56(11 Suppl. 4), S46–S51 (2001).
   PubMed Web of Science ®Google Scholar
• Mendez MF. Frontotemporal dementia: therapeutic interventions. Front. Neurol. Neurosci.24, 168–178 (2009).
   PubMedGoogle Scholar
• Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology66(1), 17–22 (2006).
   PubMed Web of Science ®Google Scholar
• Procter AW, Qurne M, Francis PT. Neurochemical features of frontotemporal dementia. Dement. Geriatr. Cogn. Disord.10(Suppl. 1), 80–84 (1999).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Markesbery WR. Altered serotonergic and cholinergic synaptic markers in Pick’s disease. Arch. Neurol.48(8), 796–799 (1991).
   PubMedGoogle Scholar
• Pasquier F, Fukui T, Sarazin M et al. Laboratory investigations and treatment in frontotemporal dementia. Annals Neurol.54(Suppl. 5), S32–S35 (2003).
   PubMed Web of Science ®Google Scholar
• Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am. J. Alzheimers Dis. Other Demen.17(5), 267–272 (2002).
   PubMedGoogle Scholar
• Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur. Neurol.49(1), 13–19 (2003).
   PubMed Web of Science ®Google Scholar
• Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology172(4), 400–408 (2004).
   PubMed Web of Science ®Google Scholar
• Lebert F, Pasquier F. Trazodone in the treatment of behaviour in frontotemporal dementia. Hum. Psychopharmacol. Clin. Exp.14(4), 279–281 (1999).
   Web of Science ®Google Scholar
• Bowen D, Procter A, Mann D et al. Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy. Psychopharmacology196(4), 603–610 (2008).
   PubMed Web of Science ®Google Scholar
• Curtis RC, Resch DS. Case of pick’s central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J. Clin. Psychopharmacol.20(3), 384–385 (2000).
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am. J. Alzheimers Dis. Other Demen.18(4), 205–214 (2003).
   PubMedGoogle Scholar
• Pijnenburg YA, Sampson EL, Harvey RJ, Fox NC, Rossor MN. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int. J. Geriatr. Psychiatry18(1), 67–72 (2003).
   PubMed Web of Science ®Google Scholar
• Wang PS, Schneeweiss S, Avorn J et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N. Engl. J. Med.353(22), 2335–2341 (2005).
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation. Int. J. Geriatr. Psychiatry17(4), 391–392 (2002).
   PubMed Web of Science ®Google Scholar
• Rahman S, Robbins TW, Hodges JR et al. Methylphenidate (‘Ritalin’) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology31(3), 651–658 (2006).
   PubMed Web of Science ®Google Scholar
• Goforth HW, Konopka L, Primeau M et al. Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study. Clin. EEG Neurosci.35(2), 108–111 (2004).
   PubMed Web of Science ®Google Scholar
• Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin. Biol. Ther.10(7), 1121–1130 (2010).
   PubMed Web of Science ®Google Scholar
• Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies. Nat. Rev. Drug Discov.8(10), 783–793 (2009).
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Clin. Interv. Aging3(2), 211–225 (2008).
   PubMed Web of Science ®Google Scholar
• Shanks M, Kivipelto M, Bullock R, Lane R. Cholinesterase inhibition: is there evidence for disease-modifying effects? Curr. Med. Res. Opin.25(10), 2439–2446 (2009).
   PubMed Web of Science ®Google Scholar
• Munoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer’s disease. Curr. Med. Chem.15(24), 2433–2455 (2008).
   PubMed Web of Science ®Google Scholar
• Hansen LA, Deteresa R, Tobias H, Alford M, Terry RD. Neocortical morphometry and cholinergic neurochemistry in Pick’s disease. Am. J. Pathol.131(3), 507–518 (1988).
   PubMed Web of Science ®Google Scholar
• Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease. Am. J. Psychiatry161(3), 532–538 (2004).
   PubMed Web of Science ®Google Scholar
• Trinh N-H, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA289(2), 210–216 (2003).
   PubMed Web of Science ®Google Scholar
• Lampl Y, Sadeh M, Lorberboym M. Efficacy of acetylcholinesterase inhibitors in frontotemporal dementia. Ann. Pharmacother.38(11), 1967–1968 (2004).
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging21(14), 931–937 (2004).
   PubMed Web of Science ®Google Scholar
• Knopman DS, Kramer JH, Boeve BF et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain131(Pt 11), 2957–2968 (2008).
   PubMed Web of Science ®Google Scholar
• Kertesz A, Morlog D, Light M et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement. Geriatr. Cogn. Disord.25(2), 178–185 (2008).
   PubMed Web of Science ®Google Scholar
• Gorno-Tempini ML, Brambati SM, Ginex V et al. The logopenic/phonological variant of primary progressive aphasia. Neurology71(16), 1227–1234 (2008).
   PubMed Web of Science ®Google Scholar
• Rabinovici GD, Jagust WJ, Furst AJ et al. Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann. Neurol.64(4), 388–401 (2008).
   PubMed Web of Science ®Google Scholar
• Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am. J. Ger. Psychiatry15(1), 84–87 (2007).
   PubMed Web of Science ®Google Scholar
• Boxer AL, Boeve BF. Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis. Assoc. Disord.21(4), S79–S87 (2007).
   PubMed Web of Science ®Google Scholar
• Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology59(7), 1077–1079 (2002).
   PubMed Web of Science ®Google Scholar
• Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology60(7), 1094–1097 (2003).
   PubMed Web of Science ®Google Scholar
• van Marum RJ. Update on the use of memantine in Alzheimer’s disease. Neuropsychiatr. Dis. Treat.5, 237–247 (2009).
   PubMed Web of Science ®Google Scholar
• Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system – too little activation is bad, too much is even worse. Neuropharmacology53(6), 699–723 (2007).
   PubMed Web of Science ®Google Scholar
• Kerchner G, Kim A, Choi D. Glutamate-mediated excitotoxicity. In: Ionotropic Glutamate Receptors in the CNS. Jonas P, Monyer H (Eds). Springer-Verlag, Berlin, Germany, 443–469 (1999).
   Google Scholar
• Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat. Rev. Drug Discov.5(2), 160–170 (2006).
   PubMed Web of Science ®Google Scholar
• Olney JW, Farber NB. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology13(4), 335–345 (1995).
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science298(5594), 789–791 (2002).
   PubMed Web of Science ®Google Scholar
• Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature443(7113), 768–773 (2006).
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J. Clin. Psychiatry69(3), 341–348 (2008).
   PubMed Web of Science ®Google Scholar
• Franco KN, Messinger-Rapport B. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. J. Am. Med. Dir. Assoc.7(3), 201–202 (2006).
   PubMed Web of Science ®Google Scholar
• Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int. J. Geriatr. Psychiatry20(5), 459–464 (2005).
   PubMed Web of Science ®Google Scholar
• Cummings JL, Schneider E, Tariot PN, Graham SM, for the Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology67(1), 57–63 (2006).
   PubMed Web of Science ®Google Scholar
• Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis. Assoc. Dis.21(2), 164–166 (2007).
   PubMed Web of Science ®Google Scholar
• Diehl-Schmid J, Förstl H, Perneczky R, Pohl C, Kurz A. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int. J. Geriatr. Psychiatry23(7), 754–759 (2008).
   PubMed Web of Science ®Google Scholar
• Boxer AL, Lipton AM, Womack K et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis. Assoc. Disord.23(3), 211–217 (2009).
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Jouroukhin Y, Gray AJ et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer’s disease. J. Pharmacol. Exp. Ther.325(1), 146–153 (2008).
   PubMed Web of Science ®Google Scholar
• Wischik C, Staff R. Challenges in the conduct of disease-modifying trials in AD: Practical experience from a Phase 2 trial of TAU-aggregation inhibitor therapy. J. Nutr. Health Aging13(4), 367–369 (2009).
   PubMed Web of Science ®Google Scholar
• Vossel KA, Miller BL. New approaches to the treatment of frontotemporal lobar degeneration. Curr. Opin. Neurol.21(6), 708–716 (2008).
   PubMed Web of Science ®Google Scholar
• Trojanowski JQ, Duff K, Fillit H et al. New directions for frontotemporal dementia drug discovery. Alzheimers Dement.4(2), 89–93 (2008).
   PubMed Web of Science ®Google Scholar
• Stamelou M, de Silva R, Arias-Carrion O et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain133(Pt 6), 1578–1590 (2010).
   PubMed Web of Science ®Google Scholar
• Cruts M, Gijselinck I, van der Zee J et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature442(7105), 920–924 (2006).
   PubMed Web of Science ®Google Scholar
• Baker M, Mackenzie IR, Pickering-Brown SM et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature442(7105), 916–919 (2006).
   PubMed Web of Science ®Google Scholar
• Jiao J, Herl LD, Farese RV, Gao FB. MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia. PLoS One5(5), e10551 (2010).
   PubMed Web of Science ®Google Scholar
• Knopman DS, Jack CR Jr, Kramer JH et al. Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year. Neurology72(21), 1843–1849 (2009).
   PubMed Web of Science ®Google Scholar